[{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Pathogen Reduced Cryoprecipitated Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase IV","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Cerus Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Cerus Corporation \/ Cerus Corporation"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pathogen-Reduced Plasma","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerus Corporation \/ Cerus Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Cerus Corporation \/ Cerus Corporation"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Intercept Plasma","moa":"SARS-CoV-2\/Pathogens","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Autologous Apheresis Platelet Component","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"NONOXYNOL-9","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"Intercept Treated Red Blood Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ BARDA"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Pathogen Reduced Lyophilized Cryoprecipitate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Cerus Corporation","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ US Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Cerus Corporation \/ US Department of Defense"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Red Blood Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"S-303","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"S303 RBCs","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Cerus Corporation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Pathogen Reduced Cryoprecipitated Fibrinogen

                          Therapeutic Area : Hematology

                          Study Phase : Phase IV

                          Recipient : Weill Medical College of Cornell University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Intercept Fibrinogen Complex (Pathogen Reduced Cryoprecipitated Fibrinogen) is a Microorganism drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypofibrinogenemia.

                          Product Name : Intercept Fibrinogen Complex

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          February 03, 2023

                          Lead Product(s) : Pathogen Reduced Cryoprecipitated Fibrinogen

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Recipient : Weill Medical College of Cornell University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Cerus’ LyoCryo, a pathogen reduced, lyophilized cryoprecipitate, is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic i...

                          Product Name : LyoCryo

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 02, 2022

                          Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Undisclosed

                          Sponsor : US Department of Defense

                          Deal Size : $9.1 million

                          Deal Type : Funding

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Pathogen-Reduced Plasma is a Microorganism drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Burns.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          December 23, 2020

                          Lead Product(s) : Pathogen-Reduced Plasma

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase IV

                          Recipient : Coalition for National Trauma Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Funding boosts further evaluation of the INTERCEPT Blood System's effectiveness in inactivating SARS-CoV-2 in all three blood components beyond what has already been identified.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          April 20, 2020

                          Lead Product(s) : Intercept Treated Red Blood Cell

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : BARDA

                          Deal Size : $214.0 million

                          Deal Type : Funding

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Autologous Apheresis Platelet Component is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 12, 2016

                          Lead Product(s) : Autologous Apheresis Platelet Component

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Intercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 08, 2014

                          Lead Product(s) : NONOXYNOL-9

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Intercept Plasma is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemorrhagic Fever, Ebola.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          November 20, 2014

                          Lead Product(s) : Intercept Plasma

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : S-303 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of beta-Thalassemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 04, 2012

                          Lead Product(s) : S-303

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : S303 RBCs is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 30, 2012

                          Lead Product(s) : S303 RBCs

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Red Blood Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          October 22, 2012

                          Lead Product(s) : Red Blood Cell

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank